Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

Sponsor
Ottawa Hospital Research Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT03481010
Collaborator
(none)
188
7
2
47.9
26.9
0.6

Study Details

Study Description

Brief Summary

At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone.

This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same time.

Condition or Disease Intervention/Treatment Phase
  • Procedure: PAO with hip arthroscopy
  • Procedure: PAO without hip arthroscopy
N/A

Detailed Description

Hip dysplasia is a developmental abnormality of the acetabulum (hip socket) that causes abnormal stresses inside the hip joint and leads to painful arthritis at a young age. Many patients develop painful symptoms in their hip before advanced arthritis occurs.

The periacetabular osteotomy (PAO) is a surgical procedure that reorients the acetabulum to reduce the stresses inside the hip joint. The PAO is very effective at improving symptoms and quality of life. However, some patients may have residual symptoms.

Frequently, people with hip dysplasia will have an MRI done before their surgery, which helps to identify other the abnormalities inside their hip joint (e.g., labral tears). These abnormalities inside the joint cannot easily be addressed through PAO alone, however they can be addressed with hip arthroscopy. Hip arthroscopy is a separate minimally invasive surgical procedure that allows the surgeon to access the inside of the hip joint with a small camera and address any abnormalities.

At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone.

This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same time. Patients will be followed for 2 years after surgery. Symptomatic differences between the two patient groups will be assessed to determine added benefit of the hip arthroscopy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
188 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology: A Multicenter Randomized Controlled Trial
Actual Study Start Date :
Apr 4, 2018
Anticipated Primary Completion Date :
Mar 31, 2022
Anticipated Study Completion Date :
Mar 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: PAO with hip arthroscopy

Patient's in the "Scope PAO" group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the "Scope-PAO" group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy.

Procedure: PAO with hip arthroscopy
Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.

Active Comparator: PAO without hip arthroscopy

Patient's in the "PAO-only" group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the "PAO-only" group have been randomized to receive a periacetabular osteotomy only.

Procedure: PAO without hip arthroscopy
Participants who are randomized to the "PAO-only" group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia.

Outcome Measures

Primary Outcome Measures

  1. iHOT-33 [24 months]

    Patient-reported quality of life will be the primary outcome used for comparison between the two treatment groups as measured by the International Hip Outcome Tool (iHOT-33). The iHOT-33 is a validated, self-administered quality of life assessment tool for young, active patients with hip symptoms.

Secondary Outcome Measures

  1. HOOS [before surgery, 6 months, 12 months, 24 months after surgery]

    Hip-specific symptoms and functional impairment will be compared using the Hip Disability and Osteoarthritis Outcome Score (HOOS). This 40-item patient reported outcome tool has been validated for use in patients with and without hip osteoarthritis and has shown good responsiveness, reliability and reproducibility in this patient population.

  2. PROMIS Global 10 [before surgery, 6 months, 12 months, 24 months after surgery]

    Global Health assessment will be compared using the PROMIS Global 10 Score. This 10-item tool assesses general domains of health related quality of life in the domains of physical, mental, and social well-being.

  3. Operative time [intra-operative]

    Total operative time is expected to be longer in the "Scope-PAO" treatment group, however the average increase in time will be valuable information for future research assessing cost-effectiveness of this treatment strategy. Total operative time will be measured from the time the patient enters the operating room to the time the patient is ready for transfer to post-anesthetic care unit (PACU). This time interval represents the best assessment of the overall time cost to the health care system associated with the surgical procedure while avoiding confounding due to delays in transfer to PACU.

  4. Hospital Length of Stay [up to one month]

    Length of stay, measured in days, will be assessed from date of admission to date of discharge up to one month.

  5. Adverse Events [2-4 weeks and 3 months after surgery]

    Adverse events will be assessed prospectively at the first and second post-operative visits using Sink et al.'s classification system that grades the complications based on required treatment and long-term morbidity.

  6. Cost-Effectiveness [6 months, 12 months, and 24 months after surgery]

    The cost-effectiveness of the two study groups will be assessed prospectively using the Work Productivity and Activity Impairment Questionnaire. This 6-item validated questionnaire quantifies work impairments. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and percentage of impairment in activities performed outside of work. Greater scores indicate greater impairment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Skeletally mature patient undergoing Bernese periacetabular osteotomy for symptomatic acetabular dysplasia/hip instability

  • Pre-Operative MRI at 3T and/or gadolinium MR arthrogram

  • Age, 16-50 years old

  • Patient capable of giving informed consent

Exclusion Criteria:
  • Prior hip/pelvis surgery of any kind on the surgical side

  • Prior hip arthroplasty surgery on either side

  • Radiographic evidence of arthritis (i.e. Tönnis grade =2)

  • Known connective tissue disorder (e.g. Ehlers-Danlos Syndrome, etc.)

  • Known neuromuscular disorder (e.g. Cerebral Palsy, Spina bifida, etc.)

  • Known skeletal dysplasia (e.g. Achondroplasia, Multiple Epiphyseal Dysplasia, etc.)

  • Cognitive impairment that prevents accurate completion of patient-reported outcome questionnaires.

  • Patient unable/unwilling to complete all required follow-up visits

  • Concurrent proximal femoral osteotomy and/or surgical hip dislocation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Chicago Illinois United States 60611
2 William Beaumont Hospital Royal Oak Michigan United States 48073
3 The Washington University Saint Louis Missouri United States 63130
4 Hospital for Special Surgery New York New York United States 10021
5 Children's Hospital of Eastern Ontario Ottawa Ontario Canada K1H 8L1
6 Ottawa Hospital Research Institute Ottawa Ontario Canada K1H8L6
7 CHU de Québec - Université Laval Québec Canada G1J 1Z4

Sponsors and Collaborators

  • Ottawa Hospital Research Institute

Investigators

  • Principal Investigator: Geoffrey Wilkin, MD, The Ottawa Hospital Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT03481010
Other Study ID Numbers:
  • 20170796
First Posted:
Mar 29, 2018
Last Update Posted:
Jun 30, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 30, 2021